公开(公告)号：US20190040141A1

公开(公告)日：2019-02-07

申请号：US15955304

申请日：2018-04-17

Applicant: Amgen Inc.

Inventor： Pedro J. BELTRAN ,  Frank J. CALZONE ,  Gregory FRIBERG ,  Christopher HAQQ ,  Anthony W. TOLCHER

IPC: C07K16/28

Abstract: The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

公开(公告)号：US20150274829A1

公开(公告)日：2015-10-01

申请号：US14552289

申请日：2014-11-24

Applicant: AMGEN INC.

Inventor： Frank J. CALZONE ,  Rajendra V. DESHPANDE ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Abstract translation: 本发明提供与抗IGF-1R抗体有关或衍生自抗IGF-1R抗体的组合物和方法。 在具体实施方案中，本发明提供了结合人IGF-1R，IGF-1R结合片段和此类抗体的衍生物的完整的人，人源化或嵌合抗IGF-1R抗体，以及包含此类片段的IGF-1R结合多肽。 其他实施方案提供编码此类抗体，抗体片段和衍生物和多肽的核酸，包含此类多核苷酸的细胞，制备此类抗体的方法，抗体片段和衍生物和多肽，以及使用此类抗体，抗体片段和衍生物和多肽的方法，包括方法 治疗或诊断具有IGF-1R相关疾病或病症的受试者。

公开(公告)号：US20130236457A1

公开(公告)日：2013-09-12

申请号：US13891781

申请日：2013-05-10

Applicant: AMGEN INC.

Inventor： Frank J. CALZONE ,  Rajendra V. DESHPANDE ,  Mei-Mei TSAI

IPC: A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.